Why GLP-1 Drugs May Improve Sleep Apnea

<p>grandriver / Getty Images</p>

grandriver / Getty Images

Fact checked by Nick Blackmer

Key Takeaways

  • Clinical trials of Eli Lilly's tirzepatide have demonstrated that participants on the medication experienced a significant reduction in obstructive sleep apnea symptoms.

  • Excess weight around the throat and airways can contribute to obstructive sleep apnea by causing tissues to collapse and block the airway.

  • If drugs like Zepbound and Wegovy are effective in treating sleep apnea, it could encourage insurance companies to expand coverage for these medications.



Obesity medications such as Wegovy (semaglutide) and Zepbound (tirzepatide) have been shown to help with conditions beyond weight loss, including heart disease and fatty liver disease. Now, we can add sleep apnea to the myriad of ailments that these drugs seem to continue to have an impact on.

Eli Lilly, the maker of Zepbound, said its phase 3 clinical trials found that participants taking tirzepatide saw a significant drop in their symptoms of obstructive sleep apnea, a condition that affects approximately 26% of Americans between the ages of 30 and 70.

In the clinical trials, scores measured by the apnea-hypopnea index (AHI), which measures the number of breathing interruptions or reductions per hour—decreased by 55% to 62.8% on average for those using the medication.

The improvement in sleep apnea symptoms is linked to weight loss, according to Mir Ali, MD, a bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center.

“Excess weight can deposit in the airways around the throat and things and make it somewhat sloppy. So the tissues kind of fall back and obstruct the airway,” Ali told Verywell. “When a patient loses weight, they lose that extra fat and tissue in their airways, so the obstructive sleep apnea goes away.”

Related: How Sleep Apnea Affects Weight

Ali said many of his patients have sleep apnea, but the condition often remains undiagnosed until confirmed through a sleep study.

Although Continuous Positive Airway Pressure (CPAP) machines are considered the “gold standard” for managing sleep apnea, they can be expensive, bulky, and challenging for patients to use in the long run.

The link between GLP-1 medications and sleep apnea is not new. A 2016 clinical trial found that weight loss resulting from liraglutide—a GLP-1 drug approved to treat obesity in 2022—could improve sleep apnea symptoms in patients.

“Weight loss can help, but some people will continue to have sleep apnea due to other causes, such as oral and airway anatomy,” said Alex Dimitriu, MD, founder of Menlo Park Psychiatry & Sleep Medicine.

Related: Surprising Signs and Symptoms of Untreated Sleep Apnea

If GLP-1 drugs prove to be helpful in improving sleep apnea, it might open up more avenues for insurance coverage. Patients who are on these medications often have to pay out-of-pocket because insurance doesn’t cover them.

“Sleep apnea is one of these medical conditions that the insurance companies deem as significant enough that they would approve surgery if they fall under a certain BMI range,” Ali said.

Dimitriu said he would like to see more research on how dental morphology—the unique features of each person’s dental anatomy—is affected by weight loss, and how sleep health intersects with weight fluctuation and the study of things like cravings.

Still, he said people need to keep in mind the limits of GLP-1 drugs when it comes to sleep apnea.

“Not all sleep apnea is from obesity, and thus, losing weight may not be an effective treatment for everyone,” Dimitriu said. “Nasal congestion, palatal, dental, and jaw structure can all play a role, and some of these may not be improved as much as obesity when someone starts losing weight.”

According to Lilly, the company will present its clinical trial results on sleep apnea later this year with the hope of applying for FDA approval shortly after.

Read Next: Convenient Home Sleep Apnea Testing Costs Less



What This Means For You

While Zepbound is not yet approved by the FDA for treating sleep apnea, there’s strong evidence that weight loss induced by this type of medication can improve symptoms significantly.



Read the original article on Verywell Health.

Advertisement